Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Five Prime plans to submit Phase 1 lead-in data for presentation at medical conference in the first half of 2019 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 10, 2018-- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology
Toggle Summary Five Prime Therapeutics to Present at 2018 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker , Chief Executive Officer, will present at the

Upcoming and Recent Events > MORE

Date Event Details
Summary Toggle Thursday, June 07, 2018 11:00 AM EDT

Speaker

Francis Sarena
Chief Strategy Officer and Secretary

Supporting Materials

Summary Toggle Thursday, June 14, 2018 8:00 AM PDT
Summary Toggle Wednesday, August 08, 2018 4:30 PM EDT